Phaseline

Targets › GRIK2

GRIK2 (Glutamate receptor ionotropic, kainate 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Nov 2026.

Ionotropic glutamate receptor that functions as a cation-permeable ligand-gated ion channel, gated by L-glutamate and the glutamatergic agonist kainic acid. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system (By similarity). (UniProt, Q13002)

Open in Phaseline: the race on GRIK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
UniQure BiopharmaAAV9-hSyn1-miGRIK2 (AMT-260)
AAV9 gene therapy delivering miRNA to silence GRIK2 and suppress GluK2-containing kainate
GRIK2Phase 1Mesial Temporal Lobe EpilepsyNov 2026

Conditions

Mesial Temporal Lobe Epilepsy (1)

Modalities

other (1)

Companies

UniQure Biopharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.